Pegsunercept: Difference between revisions
Content deleted Content added
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number'). |
→top: infobox |
||
| (14 intermediate revisions by 13 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| verifiedrevid = |
| verifiedrevid = 458269166 |
||
| IUPAC_name = |
| IUPAC_name = |
||
| ⚫ | |||
| ⚫ | |||
| tradename = |
| tradename = |
||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_status = investigational |
| legal_status = investigational |
||
| routes_of_administration = [[subcutaneous injection]] |
| routes_of_administration = [[subcutaneous injection]] |
||
| ⚫ | |||
| ⚫ | |||
| bioavailability = N/A |
| bioavailability = N/A |
||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| Line 29: | Line 27: | ||
| KEGG = D05393 |
| KEGG = D05393 |
||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = none |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| molecular_weight = 12,103 g/mol (protein part) |
|||
}} |
}} |
||
'''Pegsunercept''' is a [[pharmaceutical drug|drug]] for the treatment of [[rheumatoid arthritis]]. {{As of|2010|1}}, Phase II [[clinical trial]]s have been completed.<ref>{{ClinicalTrialsGov|NCT00037700|Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis}}</ref><ref>{{ClinicalTrialsGov|NCT00111423|Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)}}</ref><ref name="Furst">{{ |
'''Pegsunercept''' is a [[pharmaceutical drug|drug]] for the treatment of [[rheumatoid arthritis]]. {{As of|2010|1}}, Phase II [[clinical trial]]s have been completed.<ref>{{ClinicalTrialsGov|NCT00037700|Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis}}</ref><ref>{{ClinicalTrialsGov|NCT00111423|Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)}}</ref><ref name="Furst">{{cite journal | vauthors = Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M | title = A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis | journal = The Journal of Rheumatology | volume = 32 | issue = 12 | pages = 2303–10 | date = December 2005 | pmid = 16331754 }}</ref> It is being developed by [[Amgen]]. |
||
Similarly to [[etanercept]], pegsunercept is a soluble [[CD120|tumor necrosis factor receptor]]. Pegsunercept is a [[PEGylated]] protein.<ref name="Furst" /> |
Similarly to [[etanercept]], pegsunercept is a soluble [[CD120|tumor necrosis factor receptor]]. Pegsunercept is a [[PEGylated]] protein.<ref name="Furst" /> |
||
==References== |
== References == |
||
{{ |
{{Reflist}} |
||
{{Immunosuppressants}} |
{{Immunosuppressants}} |
||
{{Cytokine receptor modulators}} |
|||
[[Category:TNF |
[[Category:TNF inhibitors]] |
||
[[Category:Immunosuppressants]] |
[[Category:Immunosuppressants]] |
||
[[Category:Amgen]] |
|||
{{antineoplastic-drug-stub}} |
{{antineoplastic-drug-stub}} |
||